. 2013 Mar 8;92(7):925–933. doi: 10.1007/s00277-013-1716-2

Table 3.

Univariate analysis of prognostic factors associated with overall survival and progression-free survival

Group	No.	5-year OS (95 % CI)	p value	5-year PFS (95 %)	p value
Ann Arbor stage
I–II	14	84.6 (57.8–95.7)	0.099	78.6 (52.3–92.5)	0.10
III–IV	50	53.0 (36.5–68.8)	0.099	52.1 (36.8–67.0)	0.10
B symptoms at diagnosis
No	14	83.3 (55.1–95.3)	0.066	85.1 (58.8–95.8)	0.023
Yes	51	53.8 (37.3–69.5)	0.066	51.5 (36.6–66.2)	0.023
Bone marrow involvement at diagnosis
No	44	69.2 (50.9–82.9)	0.004	69.9 (53.7–82.3)	0.002
Yes	16	34.9 (15.1–61.9)	0.004	24.1 (8.8–51.1)	0.002
Response to induction regimen
≥PR	53	66.0 (49.9–79.1)	0.050	65.2 (50.0–77.8)	0.004
Primary refractoriness^a	12	41.0 (16.6–70.9)	0.050	33.3 (6.6–60.0)	0.004
Disease status at transplant
CR	36	65.7 (46.9–80.6)	0.46	64.5 (46.3–79.3)	0.23
less than CR	29	57.1 (35.5–76.3)	0.46	54.7 (36.5–72.9)	0.23
Number of prior chemotherapy regimen
1	19	77.2 (53.7–90.7)	0.17	78.7 (56.6–90.8)	0.08
2 or more	46	56.8 (40.7–71.6)	0.17	51.7 (36.9–66.2)	0.08
Histology
ALK-positive and ALK-unknown ALCL	13	54.2 (26.2–79.8)	0.70	59.8 (33.4–81.5)	0.89
Other types	52	63.3 (47.1–77.0)	0.70	59.3 (44.4–72.6)	0.89
ALCL-all subtypes	20	63.6 (38.8–82.8)	0.77	63.8 (41.7–81.3)	0.70
PTCL-NOS and AITL	45	60.7 (43.4–75.7)	0.77	57.5 (41.5–72.1)	0.70
ALK-positive and ALK-unknown ALCL	13	54.2 (26.2–79.8)	0.74	59.8 (33.4–81.5)	0.62
ALK-negative ALCL	7	83.3 (43.7–97.0)		71.4 (35.8–91.8)
PTCL-NOS	36	60.7 (42.3–76.5)		55.8 (39.0–71.3)
AITL	9	55.6 (18.0–87.7)		55.6 (18.0–87.7)

OS overall survival, PFS progression-free survival, CI confidence interval, CR complete response, PR partial response, ALK anaplastic lymphoma kinase, ALCL anaplastic large cell lymphoma, PTCL peripheral T cell lymphoma, NOS not otherwise specified, AITL angioimmunoblastic T cell lymphoma

^aLess than PR